Wearable heart monitors for people having treatment for breast cancer or blood cancers
Tests wearable patch heart monitors in adults having cancer treatment.
Plain-language title generated from the registry record
Registry title: Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)
Key facts
- Where
- Minneapolis, United StatesSee the site
Where in United States
- M Health Fairview Clinics and Surgery CenterMinneapolis, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Minnesota
- Trial code
- NCT07776964
- Record updated
- 2 November 2026
- Original description
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment.Read full original descriptionShow less
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment.
Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers.
Participants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.
Inclusion: Diagnosis of breast cancer, hematologic malignancy including leukemia or lymphoma, or multiple myeloma; At least 18 years of age; Capable of understanding and willing to sign a consent form for this study.
Exclusion: Known allergy to adhesive patches used for ambulatory EKG monitoring; Children; Cognitively challenged individuals; Prisoners; Active service military personnel.